[go: up one dir, main page]

NO2007009I2 - Valsartan og Amlodipin - Google Patents

Valsartan og Amlodipin

Info

Publication number
NO2007009I2
NO2007009I2 NO2007009C NO2007009C NO2007009I2 NO 2007009 I2 NO2007009 I2 NO 2007009I2 NO 2007009 C NO2007009 C NO 2007009C NO 2007009 C NO2007009 C NO 2007009C NO 2007009 I2 NO2007009 I2 NO 2007009I2
Authority
NO
Norway
Prior art keywords
hydrocarbon
carboxy
cycloaliphatic
aliphatic hydrocarbon
optionally
Prior art date
Application number
NO2007009C
Other languages
English (en)
Other versions
NO2007009I1 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25684817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2007009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2007009I1 publication Critical patent/NO2007009I1/no
Publication of NO2007009I2 publication Critical patent/NO2007009I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Record Carriers (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
NO2007009C 1990-02-19 1991-02-18 Valsartan og Amlodipin NO2007009I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH51890 1990-02-19
CH223490 1990-07-05

Publications (2)

Publication Number Publication Date
NO2007009I1 NO2007009I1 (no) 2007-07-23
NO2007009I2 true NO2007009I2 (no) 2010-09-13

Family

ID=25684817

Family Applications (5)

Application Number Title Priority Date Filing Date
NO910630A NO304023B1 (no) 1990-02-19 1991-02-18 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive acylforbindelser
NO2007009C NO2007009I2 (no) 1990-02-19 1991-02-18 Valsartan og Amlodipin
NO1999001C NO1999001I2 (no) 1990-02-19 1991-02-18 Analogifremgangsmaate for fremstilling av terapeutisk aktive acylforbindelser
NO1998024C NO1998024I1 (no) 1990-02-19 1998-10-21 Valsartan
NO2010008C NO2010008I1 (no) 1990-02-19 2010-04-14 Valsartan, amlodipin, hydroklortiazid og farmasøytiske akseptable salter derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO910630A NO304023B1 (no) 1990-02-19 1991-02-18 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive acylforbindelser

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO1999001C NO1999001I2 (no) 1990-02-19 1991-02-18 Analogifremgangsmaate for fremstilling av terapeutisk aktive acylforbindelser
NO1998024C NO1998024I1 (no) 1990-02-19 1998-10-21 Valsartan
NO2010008C NO2010008I1 (no) 1990-02-19 2010-04-14 Valsartan, amlodipin, hydroklortiazid og farmasøytiske akseptable salter derav

Country Status (26)

Country Link
US (2) US5399578A (no)
EP (1) EP0443983B1 (no)
JP (1) JP2749458B2 (no)
KR (1) KR0171409B1 (no)
AT (1) ATE134624T1 (no)
AU (1) AU644844B2 (no)
CA (2) CA2232775C (no)
CY (2) CY1978A (no)
DE (4) DE59107440D1 (no)
DK (1) DK0443983T3 (no)
ES (1) ES2084801T3 (no)
FI (2) FI107921B (no)
GR (1) GR3019155T3 (no)
HK (1) HK219996A (no)
HU (2) HU219343B (no)
IE (1) IE71155B1 (no)
IL (1) IL97219A (no)
LU (4) LU90100I2 (no)
LV (1) LV5773B4 (no)
NL (3) NL970001I2 (no)
NO (5) NO304023B1 (no)
NZ (1) NZ237126A (no)
PH (1) PH30484A (no)
PT (1) PT96799B (no)
SA (1) SA93140130A (no)
UY (1) UY23835A1 (no)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657498B2 (en) * 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
DE59208448D1 (de) * 1991-08-15 1997-06-12 Ciba Geigy Ag N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
EP0549352B1 (en) * 1991-12-27 2000-03-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as angiotensin II antagonists
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5256658A (en) * 1993-01-15 1993-10-26 Ortho Pharmaceutical Corporation Angiotensin II inhibitors
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
JPH0853424A (ja) * 1994-08-11 1996-02-27 Kureha Chem Ind Co Ltd ベンズイミダゾールスルホン酸アミド誘導体
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
WO1997030036A1 (en) * 1996-02-15 1997-08-21 Novartis Ag Aryl derivatives
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
ES2189940T3 (es) 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
KR980002035A (ko) * 1996-06-17 1998-03-30 손경식 비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
AU760663B2 (en) * 1998-06-03 2003-05-22 Gpi Nil Holdings, Inc. Small molecule sulfonamide hair growth compositions and uses
KR20010052503A (ko) 1998-06-03 2001-06-25 다니엘 피. 맥컬럼 Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IL140622A0 (en) * 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DK1096932T3 (da) * 1998-07-10 2007-10-15 Novartis Pharma Ag Antihypertensiv kombination af valsartan og calciumkanalblokker
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
EP1013273A1 (en) * 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
DK1588706T3 (da) 1998-12-23 2012-01-16 Novartis Ag Valsartantablet
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP4374102B2 (ja) * 1999-09-24 2009-12-02 住友化学株式会社 Ｎ，ｎ−ジイソプロピルエチルアミンの分離方法
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
MXPA02006134A (es) 1999-12-21 2002-12-13 Guilford Pharm Inc Compuestos derivados de hidantoina, composiciones farmaceuticas y metodos de uso de los mismos.
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
US20030207930A1 (en) * 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7531576B2 (en) * 2000-12-26 2009-05-12 Pola Chemical Industries, Inc. Biphenyl derivatives
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
NZ531346A (en) * 2001-08-28 2005-10-28 Sankyo Co Medicinal compositions containing angiotensin II receptor antagonist
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
US20040072886A1 (en) * 2002-04-15 2004-04-15 Dr. Reddy's Laboratories Limited Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RS20050106A (sr) 2002-08-19 2007-11-15 Pfizer Products Inc., Kombinovana terapija hiperproliferativnih bolesti
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
US20050165075A1 (en) * 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
US7010633B2 (en) * 2003-04-10 2006-03-07 International Business Machines Corporation Apparatus, system and method for controlling access to facilities based on usage classes
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
AU2003245037A1 (en) * 2003-06-16 2005-01-04 Hetero Drugs Limited A novel process for preparation of valsartan
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
CA2536781A1 (en) * 2003-08-27 2005-03-10 Zentiva, A.S. A method of removing the triphenylmethane protecting group
EP1668008A4 (en) * 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
PL1673107T3 (pl) * 2003-10-10 2008-06-30 Abbott Laboratories Gmbh Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
JP4793692B2 (ja) 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
CZ298471B6 (cs) * 2004-05-19 2007-10-10 Zentiva, A.S. Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu
CN101119747A (zh) * 2004-07-02 2008-02-06 三共株式会社 组织因子产生抑制剂
CN101102755B (zh) 2004-10-08 2013-01-02 诺瓦提斯公司 肾素抑制剂在制备预防或治疗舒张功能障碍或舒张性心力衰竭的药物中的用途
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1838681A2 (en) 2004-12-22 2007-10-03 Enantia, S.L. Intermediate compounds for the preparation of an angiotensin ii receptor and process for the preparation of valsartan
DK2033629T3 (da) 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
US7659406B2 (en) * 2005-01-03 2010-02-09 Dr. Reddy's Laboratories Limited Process for preparing valsartan
US20060270723A1 (en) * 2005-01-11 2006-11-30 Tamas Koltai Process for preparing amorphous valsartan
EP1714963A1 (en) * 2005-04-19 2006-10-25 IPCA Laboratories Limited Process for the Preparation of Valsartan and its Intermediates
EP1896433A4 (en) * 2005-05-25 2010-06-02 Ipca Lab Ltd NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
EP1812411A2 (en) * 2005-07-05 2007-08-01 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AT502219B1 (de) * 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
US20070032533A1 (en) * 2005-08-08 2007-02-08 Nitromed, Inc. Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use
EP1926705B3 (en) * 2005-08-22 2010-09-15 Alembic Limited Process for preparing valsartan
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20070141533A1 (en) * 2005-12-20 2007-06-21 Ford Christopher W Polymeric dental implant assembly
US20070166372A1 (en) * 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
WO2007088558A2 (en) * 2006-02-02 2007-08-09 Alembic Limited A process for purification of valsartan
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride
EP2057132A2 (en) * 2006-07-03 2009-05-13 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
WO2008023336A2 (en) 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CA2672023A1 (en) * 2006-12-14 2008-06-19 Ratiopharm Gmbh Process for the preparation of valsartan and intermediate products
SG185318A1 (en) 2007-01-12 2012-11-29 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2139473A1 (en) * 2007-03-29 2010-01-06 Alembic Limited Valsartan tablet formulations
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
US8288561B2 (en) * 2007-05-07 2012-10-16 Cipla Limited Process for preparing valsartan
US20080299218A1 (en) * 2007-06-01 2008-12-04 Protia, Llc Deuterium-enriched valsartan
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
ATE412640T1 (de) * 2007-06-07 2008-11-15 Inke Sa Verfahren zur gewinnung eines zur gewinnung von valsartan nützlichen valsartan-salzes
EP2167477B1 (en) * 2007-06-27 2013-02-27 Mylan Laboratories Limited Process for preparing pure valsartan
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
CN101889015B (zh) * 2007-10-05 2014-06-04 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
US20100267787A1 (en) 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
EP2225210B1 (en) 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US8492577B2 (en) * 2008-04-07 2013-07-23 Hetero Research Foundation Process for preparation of valsartan intermediate
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
KR100995734B1 (ko) 2008-05-28 2010-11-19 일동제약주식회사 발사르탄의 개선된 제조방법
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010011821A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
AU2009302285A1 (en) * 2008-10-10 2010-04-15 Janssen Pharmaceutica Nv Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
KR101012135B1 (ko) 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
EP2451782B1 (en) 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Dual-acting pyrazole antihypertensive agents
US8372984B2 (en) 2009-07-22 2013-02-12 Theravance, Inc. Dual-acting oxazole antihypertensive agents
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
EP2316821A1 (en) * 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
KR101152144B1 (ko) * 2010-02-01 2012-06-15 경동제약 주식회사 발사르탄의 제조 방법 및 이에 사용되는 신규 중간체
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011124655A1 (en) * 2010-04-07 2011-10-13 Krka, D.D., Novo Mesto Improved process for preparing valsartan
KR20130075740A (ko) 2010-04-19 2013-07-05 카르디올린크스 아게 혈관 질환 및 대사성 질환을 치료하기 위한 산화질소 공여체를 갖는 발사르탄 유도체
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US8981109B2 (en) 2010-07-02 2015-03-17 Aurobindo Pharma Ltd Process for the preparation of valsartan
TR201005419A2 (tr) 2010-07-05 2012-01-23 B�Lg�� Mahmut Valsartan içeren farmasötik bileşim.
AR082435A1 (es) 2010-08-03 2012-12-05 Novartis Ag Valsartan altamente cristalino
ES2576179T3 (es) 2010-08-23 2016-07-06 Novartis Ag Proceso para la preparación de intermediarios para la elaboración de inhibidores de NEP
EP2608784B1 (en) 2010-08-24 2018-09-19 Novartis AG Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012154249A1 (en) * 2011-02-17 2012-11-15 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
KR101373705B1 (ko) 2011-08-05 2014-03-14 동국대학교 산학협력단 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
EP2797580A2 (en) 2011-12-26 2014-11-05 Novartis AG Tablets and dry-coated agents
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
AU2013255050B2 (en) 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3943084A1 (en) 2012-08-24 2022-01-26 Novartis AG Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
WO2014118721A1 (en) 2013-01-30 2014-08-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage forms comprising valsartan and nebivolol
AU2014230304B2 (en) 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
HUE047186T2 (hu) 2013-08-26 2020-04-28 Novartis Ag Új alkalmazás
WO2015030711A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
WO2015056219A1 (en) 2013-10-18 2015-04-23 Ranbaxy Laboratories Limited Process for simultaneous drying and micronization of valsartan
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072386A (zh) * 2014-06-28 2014-10-01 浙江华海药业股份有限公司 一种缬沙坦中间体的改进方法
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6382736B2 (ja) * 2015-02-02 2018-08-29 株式会社トクヤマ バルサルタンの製造方法
HUE071910T2 (hu) 2015-05-11 2025-10-28 Novartis Ag Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
WO2016201238A1 (en) 2015-06-12 2016-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of trisodium valsartan: sacubitril
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
ES2839248T5 (es) 2015-07-23 2024-02-22 Bayer Pharma AG Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
EP3411018A1 (en) 2016-02-03 2018-12-12 Novartis AG Galenic formulations of organic compounds
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
CN107056720A (zh) * 2016-12-30 2017-08-18 湖南千金湘江药业股份有限公司 一种缬沙坦的制备和纯化方法
EP3342400A1 (en) 2016-12-31 2018-07-04 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. A pharmaceutical composition comprising valsartan and chlorthalidone
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
LT3648761T (lt) 2017-07-07 2024-06-10 Boehringer Ingelheim Vetmedica Gmbh Telmisartanas, skirtas kačių hipertenzijos profilaktikai arba gydymui
ES2881317T3 (es) 2017-07-28 2021-11-29 Synthon Bv Composición farmacéutica que comprende sacubitrilo y valsartán
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
JP2021521173A (ja) 2018-04-11 2021-08-26 オハイオ・ステイト・イノベーション・ファウンデーション 眼内薬物送達用の持続放出微粒子のための方法及び組成物
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10548838B1 (en) 2018-12-14 2020-02-04 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
US11446243B1 (en) 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
ES3048170T3 (en) 2019-12-02 2025-12-09 Harman Finochem Ltd A process for the preparation of highly pure valsartan
EP3939967A1 (en) 2020-07-15 2022-01-19 KRKA, d.d., Novo mesto A continuous process for the preparation of (s)-methyl n-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-n-pentanoylvalinate in a flow reactor
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
CN113387805B (zh) * 2021-07-21 2024-01-12 黑龙江立科新材料有限公司 基于烷基重氮盐取代反应的化合物的制备方法
WO2023118482A1 (en) 2021-12-24 2023-06-29 Sun Chemical Corporation Amine synergists with uv-a absorption
WO2024019957A1 (en) * 2022-07-18 2024-01-25 Celgene Corporation Compounds for the treatment of neurodegenerative diseases
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
US20250195525A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973975A (en) * 1962-05-23 1964-11-04 Painton & Co Ltd Improvements in or relating to electric switches
SE307365B (no) * 1966-05-28 1969-01-07 Yoshitomi Pharmaceutical
US4301169A (en) * 1978-11-14 1981-11-17 Eisai Co., Ltd. Novel imidazole compound and anti-depressing agent containing the same
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4333943A (en) * 1980-04-24 1982-06-08 Miles Laboratories, Inc. Ethyl 3-(3-indolyl)-3-(5-tetrazolyl) propionate compounds used as anti-hypertensive agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
EP0142754A2 (en) * 1983-11-04 1985-05-29 Ferrer Internacional, S.A. 2-Substituted-benzoic acid imidazoles, process for preparing them and pharmaceutical compositions containing them
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
US4578386A (en) * 1984-02-10 1986-03-25 Usv Pharmaceutical Corp. 7,8-Dihydroimidazo[1,5-a]pyrazin-8-ones
US4755518A (en) * 1985-12-20 1988-07-05 Warner-Lambert Company Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof
US4748245A (en) * 1986-03-20 1988-05-31 Stauffer Chemical Company Process for making phenylthiopyrimidines
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US4870186A (en) * 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4874867A (en) * 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4921632A (en) * 1987-08-26 1990-05-01 Nec Corporation Liquid crystal compounds and compositions
US5189048A (en) * 1988-01-07 1993-02-23 E. I. Du Pont De Nemours And Company Substituted 1,2,3 triazole angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
ES2142789T3 (es) * 1989-06-14 2000-05-01 Smithkline Beecham Corp Acidos imidazolil-alquenoicos.
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
FI916130A7 (fi) * 1989-06-30 1991-12-27 Du Pont Aryylisubstituoituja imidatsoleja
AU644802B2 (en) * 1989-06-30 1993-12-23 E.I. Du Pont De Nemours And Company Substituted imidazoles
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
ATE113281T1 (de) * 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
ATE117294T1 (de) * 1989-08-11 1995-02-15 Ici Plc Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
US5298518A (en) * 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
JPH03223281A (ja) * 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
EP0522038A4 (en) * 1990-03-30 1993-05-26 Merck & Co. Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides

Also Published As

Publication number Publication date
LV5773A4 (lv) 1996-12-20
DE19675036I2 (de) 2004-10-21
FI910747A0 (fi) 1991-02-15
DE122010000024I1 (de) 2010-07-08
FI980787A7 (fi) 1998-04-06
CA2036427A1 (en) 1991-08-20
US5965592A (en) 1999-10-12
JPH04235149A (ja) 1992-08-24
GR3019155T3 (en) 1996-05-31
KR910021387A (ko) 1991-12-20
NO2010008I1 (no) 2010-05-03
NO910630L (no) 1991-08-20
HU220073B (hu) 2001-10-28
NL980036I2 (nl) 2001-02-01
PH30484A (en) 1997-05-28
NO2007009I1 (no) 2007-07-23
AU644844B2 (en) 1993-12-23
EP0443983A1 (de) 1991-08-28
IE910548A1 (en) 1991-08-28
IL97219A0 (en) 1992-05-25
DE122007000050I1 (de) 2007-11-08
LV5773B4 (lv) 1997-04-20
EP0443983B1 (de) 1996-02-28
HU9100537D0 (en) 1991-09-30
IL97219A (en) 1995-12-08
NO1998024I1 (no) 1998-10-21
HUT61271A (en) 1992-12-28
NO304023B1 (no) 1998-10-12
CA2232775A1 (en) 1991-08-20
NO1999001I2 (no) 2007-04-23
CA2232775C (en) 2003-06-10
JP2749458B2 (ja) 1998-05-13
HU9802895D0 (en) 1999-02-01
NZ237126A (en) 1994-11-25
CA2036427C (en) 1998-12-29
FI980787L (fi) 1998-04-06
FI107921B (fi) 2001-10-31
PT96799B (pt) 1998-09-30
DK0443983T3 (da) 1996-03-18
AU7115191A (en) 1991-08-22
HU219343B (en) 2001-03-28
NO910630D0 (no) 1991-02-18
NL980036I1 (nl) 1999-02-01
IE71155B1 (en) 1997-01-29
US5399578A (en) 1995-03-21
FI980787A0 (fi) 1998-04-06
SA93140130A (ar) 2005-12-03
SA93140130B1 (ar) 2005-10-16
NL970001I1 (nl) 1997-03-03
LU91676I2 (fr) 2010-06-07
KR0171409B1 (ko) 1999-02-01
HK219996A (en) 1997-01-03
UY23835A1 (es) 1995-03-21
CY2010009I2 (el) 2010-07-28
DE59107440D1 (de) 1996-04-04
LU90100I2 (fr) 1997-09-25
LU91347I2 (fr) 2009-01-14
FI910747A7 (fi) 1991-08-20
CY1978A (en) 1997-09-05
NL970001I2 (nl) 1997-06-02
ES2084801T3 (es) 1996-05-16
LU90362I2 (fr) 1999-05-10
ATE134624T1 (de) 1996-03-15
PT96799A (pt) 1991-10-31
NL300285I1 (nl) 2007-10-01
CY2010009I1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
NO2007009I2 (no) Valsartan og Amlodipin
TW427996B (en) Novel triazolopyrimidines and their use as medicaments
CA2263983A1 (en) Cyclic amine derivatives for inhibiting blood platelet aggregation
NO892952L (no) 4-oksokinolin-3-karboksylsyrederivater, fremgangsmaate tilfremstilling av og anvendelse av samme.
IL110254A0 (en) Phenalkylamines and their use
BG103329A (en) Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents
ES536413A0 (es) Procedimiento para preparar la n-(3-trifluorometilfenil)-n'-propargil-piperazina
HUP9701381A2 (hu) Új 7,8-dihidro-8,8-diszubsztituált-9H-1,3-dioxolo-[4,5-h][2,3]-benzodiazepin-származékok, ilyen hatóanyagot tartalmazó gyógyászati készítmény, és eljárás a hatóanyag előállítására